
The US FDA grants full approval for Tivdak (tisotumab vedotin-tftv), a treatment for recurrent or metastatic cervical cancer after chemotherapy, developed by Pfizer Inc. and Genmab A/S. The approval is based on the Phase 3 innovaTV 301 trial, demonstrating significant overall survival benefits compared to chemotherapy. Tivdak, an antibody-drug conjugate, received accelerated approval in 2021 and now gains full approval. The safety profile aligns with known risks. The approval signifies a crucial advance for patients with limited treatment options in advanced cervical cancer. Cervical cancer remains a significant health challenge, with high recurrence rates despite preventive measures.
Like
Save
Share